PARP Inhibitor Benefit Gets a TWiST in Recurrent Ovarian Cancer
March 17, 2019 6:00 pmBy Ian Ingram
In delaying disease progression in recurrent ovarian cancer, maintenance therapy with the PARP inhibitor niraparib (Zejula) also increased patients’ time without symptoms or toxicity (TWiST), an analysis of the phase III NOVA trial found.
Compared with placebo, … Read more